The petition could have some valid points, said Soumit Roy, an analyst with JonesTrading who has the highest price target on Wall Street at $215. But it is also potentially “over-interpreted with excessive digital analysis of figures published 15+ years ago in [a] few instances,” he said in a note to clients.
JonesTrading 的分析师 Soumit Roy 表示,请愿书可能有一些有效的观点,他在华尔街的目标价最高,为 215 美元。 但他在给客户的一份报告中说,但它也可能“在少数情况下对 15 多年前发布的数字进行过度的数字分析而过度解读”。
For Mayank Mamtani, an analyst with B. Riley Securities, investors should buy Cassava shares on weakness following the petition.
对于 B. Riley Securities 的分析师 Mayank Mamtani 来说,投资者应该在请愿书后因疲软而购买木薯股票。
“To our knowledge, citizen petitions are commonly associated with public endorsement (or lack thereof) of drug effects from experts and medical associations, rather than from law firms representing anonymous clients without disclosing conflict of interest,” he wrote.
"据我们所知,公民请愿通常与专家和医学协会对药物作用的公开认可(或缺乏认可)有关,而不是来自代表匿名客户但未披露利益冲突的律师事务所,”他写道。
Web Reference: https://finance.yahoo.com/news/meme-stock-cassava-tumbles-alzheimer-124517595.html
总之,到目前为止,还没有任何个人或组织针对SAVA药物Simufilam对于阿尔茨海默氏病的疗效以及安全性提出质疑。这应该是不幸之中的大幸!一旦SAVA宣布开始三期实验,SAVA就有可能起死回生了 。。。。。。